- Latest available (Revised)
- Original (As adopted by EU)
Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
This version of this Regulation was derived from EUR-Lex on IP completion day (31 December 2020 11:00 p.m.). It has not been amended by the UK since then. Find out more about legislation originating from the EU as published on legislation.gov.uk.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
CHAPTER III AUTHORISATION PROCEDURE FOR A SUBSTANTIAL MODIFICATION OF A CLINICAL TRIAL
Article 17.Validation of an application for the authorisation of a substantial modification of an aspect covered by Part I of the assessment report
Article 18.Assessment of a substantial modification of an aspect covered by Part I of the assessment report
Article 19.Decision on the substantial modification of an aspect covered by Part I of the assessment report
Article 20.Validation, assessment and decision regarding a substantial modification of an aspect covered by Part II of the assessment report
Article 21.Substantial modification of aspects covered by Parts I and II of the assessment report
Article 22.Assessment of a substantial modification of aspects covered by Parts I and II of the assessment report — Assessment of the aspects covered by Part II of the assessment report
Article 23.Decision on the substantial modification of aspects covered by Parts I and II of the assessment report
Article 24.Persons assessing the application for a substantial modification
CHAPTER VI START, END, TEMPORARY HALT, AND EARLY TERMINATION OF A CLINICAL TRIAL
Article 36.Notification of the start of a clinical trial and of the end of the recruitment of subjects
Article 37.End of a clinical trial, temporary halt and early termination of a clinical trial and submission of the results
Article 38.Temporary halt or early termination by the sponsor for reasons of subject safety
Article 39.Update of the contents of the summary of results and summary for laypersons
CHAPTER VII SAFETY REPORTING IN THE CONTEXT OF A CLINICAL TRIAL
Article 47.Compliance with the protocol and good clinical practice
Article 49.Suitability of individuals involved in conducting the clinical trial
Article 51.Traceability, storage, return and destruction of investigational medicinal products
Article 53.Other reporting obligations relevant for subject safety
Article 56.Recording, processing, handling and storage of information
CHAPTER XIII SUPERVISION BY MEMBER STATES, UNION INSPECTIONS AND CONTROLS
APPLICATION DOSSIER FOR THE INITIAL APPLICATION
6. The cover letter shall specify the EU trial number and...
8. The cover letter shall indicate where the information listed in...
9. The cover letter shall indicate if the clinical trial is...
10. The cover letter shall indicate if the methodology of the...
11. The cover letter shall indicate the location in the application...
12. In the case of a resubmission, the cover letter shall...
14. The protocol shall describe the objective, design, methodology, statistical considerations,...
16. The protocol shall, when possible, be written in an easily...
18. If a clinical trial is conducted with an active substance...
19. With regard to the notification of adverse events, the protocol...
21. In case the sponsor intends to submit a single safety...
22. Issues regarding labelling and the unblinding of investigational medicinal products...
23. The protocol shall be accompanied by the Charter of the...
24. The protocol shall be accompanied by a synopsis of the...
F. DOCUMENTATION RELATING TO COMPLIANCE WITH GOOD MANUFACTURING PRACTICE (GMP) FOR...
31. As regards documentation relating to GMP compliance, the following shall...
32. No documentation needs to be submitted where the investigational medicinal...
33. If the investigational medicinal product is not authorised, and does...
34. In all other cases, a copy of the authorisation referred...
35. For processes related to investigational medicinal products set out in...
G. INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER (IMPD)
36. The IMPD shall give information on the quality of any...
1.1. Data relating to the investigational medicinal product
Non-clinical pharmacology and toxicology data
41. The IMPD shall also contain summaries of non-clinical pharmacology and...
42. Non-clinical pharmacology and toxicology data shall be submitted in a...
43. The IMPD shall provide a critical analysis of the data,...
44. The IMPD shall contain a statement of the good laboratory...
45. The test material used in toxicity studies shall be representative...
I. SCIENTIFIC ADVICE AND PAEDIATRIC INVESTIGATION PLAN (PIP)
J. CONTENT OF THE LABELLING OF THE INVESTIGATIONAL MEDICINAL PRODUCTS
K. RECRUITMENT ARRANGEMENTS (INFORMATION PER MEMBER STATE CONCERNED)
L. SUBJECT INFORMATION, INFORMED CONSENT FORM AND INFORMED CONSENT PROCEDURE (INFORMATION...
M. SUITABILITY OF THE INVESTIGATOR (INFORMATION PER MEMBER STATE CONCERNED)
N. SUITABILITY OF THE FACILITIES (INFORMATION PER MEMBER STATE CONCERNED)
O. PROOF OF INSURANCE COVER OR INDEMNIFICATION (INFORMATION PER MEMBER STATE...
P. FINANCIAL AND OTHER ARRANGEMENTS (INFORMATION PER MEMBER STATE CONCERNED)
Q. PROOF OF PAYMENT OF FEE (INFORMATION PER MEMBER STATE CONCERNED)...
R. PROOF THAT DATA WILL BE PROCESSED IN COMPLIANCE WITH UNION...
1. REPORTING OF SERIOUS ADVERSE EVENTS BY THE INVESTIGATOR TO THE...
2. REPORTING OF SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTIONS (SUSARS) BY THE...
CONTENT OF THE SUMMARY OF THE RESULTS OF THE CLINICAL TRIAL FOR LAYPERSONS
LABELLING OF INVESTIGATIONAL MEDICINAL PRODUCTS AND AUXILIARY MEDICINAL PRODUCTS
The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: